Japan has sent out a quiet but concerning message that could have a huge influence on the growing number of cancer survivors in India. A long-term study of the population has found that therapy-related acute myeloid leukaemia (tAML), an uncommon but deadly blood disease, is slowly rising among people who have already been treated for other cancers, especially breast cancer. The results, which were published in the peer-reviewed journal CANCER, pose an uncomfortable question: are treatments that save lives now setting the stage for a new disaster in the future? 

Researchers looked at 30 years' worth of data from the Osaka Cancer Registry, which tracked 9,841 patients who were diagnosed with acute myeloid leukaemia (AML) between 1990 and 2020. Of these, 636 instances, or around 6.5%, were related to therapy. This means they came after chemotherapy or radiation for a separate cancer. The number of tAML cases went grown by almost three times, from 0.13 per 100,000 individuals in 1990 to 0.36 per 100,000 persons in 2020. Even more startling, the number of tAML cases almost doubled during this time.

tAML is not merely another type of malignancy. It moves quickly and is often tougher to treat. In simple terms, this condition happens when the bone marrow, which makes blood, starts making strange white blood cells after being hurt by cancer treatment. Chemotherapy and radiation can harm healthy DNA as well as tumours. This damage could lead to a second malignancy over time. 

Kenji Kishimoto, the lead author from the Osaka International Cancer Institute, said, "The study is an important step toward better understanding how the nature of tAML is changing as more people survive cancer." 

According to the study, breast cancer is becoming a more common cause of tAML, making up 14.6% of all cases. In India, where a lot of breast cancer patients are diagnosed at later stages, this aspect should not be missed. In Japan, screening generally finds cancer early, whereas many Indian patients come in when the disease has already spread. Because of this, doctors have to employ stronger combinations of chemotherapy medications and higher doses of radiation. These therapies are more likely to induce DNA damage that lasts a long time. 

This is the problem. In many places in India and the Global South, the way cancer care is done is based on both science and money. Newer, more tailored treatments that work better on cancer cells are typically too pricey for most people to acquire. Doctors depend on older, broad-spectrum chemotherapy treatments a lot because of this. These drugs work and are cheap, but they are also more dangerous to the bone marrow. Some of them, like alkylating chemicals, function by directly destroying DNA. This can cause malignancies like tAML many years later. 

The absence of information makes the issue even worse. Japan's strong cancer registration system makes it possible for the country to discover these things out. India, on the other hand, does not yet have a full national system for keeping track of long-term effects like secondary malignancies. This makes a dangerous blind area. We don't know how big the problem is without data. Policy action is delayed when there is no visibility. 

In many ways, the growth of tAML is a result of success. More people are living after cancer than ever before. But just being alive isn't enough anymore. Now the focus needs to be on what occurs when treatment is over. 

Experts in public health warn that this is a time when things need to change quickly. India requires an organised "Survivorship Watch" program, maybe run by the Indian Council of Medical Research, to keep an eye on patients who have had high-risk treatments. Long-term follow-up should be required, not just a choice. We need to look at treatment procedures again, not just to see if they work, but also to see if they are safe in the long run. 

The statistics from Japan is not something to worry about right now. It is a sign of trouble. And if it is not dealt with, it might become a crisis that India isn't ready to measure, let alone deal with.